Pharmacologic and pharmacokinetic profile of mibefradil, a T- and L- type calcium channel antagonist

Darrell R. Abernethy

Research output: Contribution to journalArticlepeer-review

Abstract

Mibefradil is a recently introduced calcium antagonist that, as a tetralol derivative, is chemically distinct from previous calcium antagonists. This article will review pertinent results from in vitro, animal, and clinical investigations to report the pharmacologic properties that distinguish mibefradil from all of the calcium channel antagonists in use today, all of which operate on the 'L-type' calcium channel. Mibefradil's pharmacokinetic profile indicates it can be used as a once-daily oral treatment for hypertension and chronic stable angina pectoris.

Original languageEnglish (US)
Pages (from-to)4C-11C
JournalAmerican Journal of Cardiology
Volume80
Issue number4 B
DOIs
StatePublished - Aug 21 1997

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Fingerprint Dive into the research topics of 'Pharmacologic and pharmacokinetic profile of mibefradil, a T- and L- type calcium channel antagonist'. Together they form a unique fingerprint.

Cite this